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Introduction
Cyclooxygenase-1 [COX-1, prostaglandin synthase] catal-
yses the transformation of arachidonic acid to the unsta-
ble intermediate prostaglandin PGH2. Subsequently,
thromboxane synthase acts on PGH2 to form TXA2, a tran-
sient biological product that induces platelet aggregation
and is a powerful vasoconstrictor. Aspirin acts primarily
by interfering with the biosynthesis of cyclic prostanoids:
TXA2, prostacyclin, and other prostaglandins. It irreversi-
bly inhibits COX-1 by acetylation of serine-530 and
induces a long-lasting functional defect in the platelets.
The resultant decrease in production of prostaglandins
and TXA2 probably accounts for much of aspirin's anti-
thrombotic effect [1,2]. The plasma half-life of aspirin is
only 20 min in circulating blood. It is rapidly deacetylated
and converted to salicylate in vivo. Salicylate does not
affect COX-1 or COX-2 activity [3].
Because platelets cannot generate new COX, the effects of
aspirin last for the duration of the life of the platelet [10
days]. After a single dose of aspirin, platelet COX activity
recovers by 10% per day in parallel with platelet turnover.
Although it may take 10 days for the total platelet popula-
tion to be renewed, it has been shown that if as few as
20% of the platelets have normal COX activity, hemosta-
sis may be normal.
TXA2 and PGI2 have opposing effects on hemostasis but
the data suggest that the antithrombotic effects of TXA2
inhibition predominate over the possible prothrombotic
effects of PGI2 inhibition [2].
The usual anti-thrombotic dose of ASA ranges from 80 to
500 mg/day. Platelet inhibition, as indicated by
aggregometry, occurs very rapidly: within 5 min of inges-
tion of 320 mg lysine acetylsalicylate, or within 30 to 60
min of oral 320 mg acetylsalicylic acid administration [4].
As COX-1 inhibition by aspirin is irreversible, there is a
cumulative inhibition of TXA2  generation by platelets
when low doses of aspirin are administered chronically
[5]. There is a non-linear relationship between inhibition
of platelet TXA2  generation and inhibition of TXA2-
dependent platelet aggregation. More than 95% inhibi-
tion of TXA2 generation is necessary to influence function
[6]. With low aspirin doses, platelet thromboxane falls
below 95% only after several days. Nevertheless, low-dose
[40 to 60 mg] as well as high-dose [500 mg] aspirin sup-
presses thromboxane A2 synthesis by >95% [7,8].
Although aspirin at high doses is anti-inflammatory due
to inhibition of COX-2, it is 170-fold more potent in
inhibiting COX-1 than COX-2 [9]. Low aspirin doses that
have little or no measurable anti-inflammatory effect
leave vascular prostacyclin formation almost intact [10].
Doses of aspirin in excess of 80 mg/d result in substantial
inhibition of endogenous prostacyclin biosynthesis [11].
Two hours after 150 mg aspirin intake, 81 to 100 per cent
inhibition of prostacyclin synthesis was demonstrated
[12].
Epidemiological studies have indicated that very low and
very high doses of aspirin [30–1500 mg] have equivalent
anti-thrombotic effects, suggesting that inhibition of
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platelet COX-1 is indeed the crucial target of aspirin [10].
This supports the view that inhibition of platelet COX-1
by low doses is sufficient to explain the cardio-protective
effect of aspirin observed in clinical trials [1]. Aspirin
reduces the risk of secondary events by about 25% in car-
diovascular diseases [13] but some patients have recurrent
vascular events in spite of aspirin therapy. It has been pro-
posed that these patients are resistant to aspirin's anti-
thrombotic effect.
Nevertheless, as published by Syrbe et al., [14] individual
dose of aspirin seems to be necessary to full inhibition of
ex-vivo platelet aggregation. Thus adjusted dose of aspirin
for individuals with cardiovascular diseases could be nec-
essary to prevent failure (aspirin resistance?) of therapy
Failures of aspirin to protect against arterial 
thrombotic events
Failure of aspirin to produce the expected inhibition of
platelet function might be attributed to several mecha-
nisms. Many individuals treated with aspirin do not
achieve the inhibitory response anticipated on the basis of
laboratory measurements of platelet activation and aggre-
gation, a phenomenon termed "aspirin resistance" [15].
Antiplatelet drugs that are effective and safe in one indi-
vidual may be ineffective in another. Aspirin is a weak
platelet inhibitor, so on its own it does not provide suffi-
cient antithrombotic therapy in some clinical or experi-
mental circumstances. It seems that resistance to aspirin
may be associated with an increase of arterial thrombotic
events in spite of chronic intake. In ex vivo assays using
aggregometry, with sodium arachidonate as agonist, aspi-
rin inhibits platelet aggregation irreversibly in most peo-
ple. However, in several patients, aspirin does not afford
the degree of platelet inhibition needed to preclude events
according to in vitro assessments [16-18].
Gum, Topol and co-workers [19] found a significant cor-
relation between aspirin resistance as measured by plate-
let aggregation and the composite primary outcome of
death, myocardial infarction, or cerebrovascular accident
in patients with stable cardiovascular disease. Of the 326
patients studied, 17 [5.2%] were resistant to 325 mg/day
aspirin. Insufficient inhibition of platelet aggregation by
aspirin ["aspirin resistance"] has been observed in 6–24%
of patients with stable coronary artery disease: by optical
aggregation, 5.5% of the patients were aspirin resistant
and 23.8% were aspirin semi-responders.
The PFA-100 [Platelet Function Analyzer, Dade] is a
device that simulates platelet function in vitro at high
shear. The test is performed by combining 2 agonists in
cartridge form: collagen/ADP and collagen/epinephrine.
Closure time is the time required for platelets to effect full
occlusion of an aperture cut into a membrane coated with
the pair of agonists. Under standardized flow conditions,
platelet activation and aggregation slowly build a stable
platelet plug at the aperture [20]. The PFA-100 system
allows quantitative assessment of platelet function,
reporting platelet aggregability as the time required to
close the small aperture in the biologically active mem-
brane. This analyzer detects no difference between the
effects of low and high-dose aspirin on platelet function
[21]. In the study by Gum and co-workers, 9.5% of
patients were aspirin resistant [19] according to the PFA-
100.
Aspirin resistance is significantly associated with an
increased risk of death, myocardial infarction or cerebrov-
ascular accident compared with aspirin-sensitive patients
[24% vs. 10%, P = 0.03] [22]. This study suggests that
aspirin non-responders might obtain less benefit with
respect to cardiovascular events. Aspirin non-responder
status may contribute to failure of aspirin therapy in the
secondary prevention of cerebrovascular incidents in as
many as 30–40 % of patients [23].
In the paper by Eikelboom et al. [24], 488 patients who
suffered myocardial infarction or stroke or died from car-
diovascular causes were compared with 488 patients who
had no cardiovascular event; all 976 patients took aspirin.
The patients in the highest quartile of urinary 11-dehydro-
thromboxane B2 excretion levels [i.e. those who were least
affected by aspirin intake] had a 3·5-fold higher risk of
cardiovascular death compared with those in the lowest
quartile [24].
With documented evidence of congestive heart failure
[left ventricular ejection fraction <40% and New York
Heart Association class II to IV symptoms], 88 outpatients
who had been treated with aspirin 325 mg/day for ≥1
month were included in the study by Sane et al.[25]. Plate-
lets were stimulated with 5 µM of adenosine diphosphate
[ADP], 1 µg/ml of collagen or 5 µM of epinephrine, and
aggregation was assessed using a Chronolog Lumi-
Aggregometer. Whole blood aggregation was determined
using the Chronolog device and the sample was stimu-
lated with 4 µg/ml of collagen. Platelet receptor expres-
sion was assessed by flow cytometry. The effect of shear
stress on platelet function was analyzed using the PFA-
100. Closure times were determined using collagen/
epinephrine test cartridges. Patients were considered aspi-
rin non-responsive when 4 of the 5 parameters assayed
were observed. Persistent platelet activation despite aspi-
rin therapy was detected in 50 of the 88 patients [56.8%].
Using the criterion of closure time ≤193 s with the colla-
gen/epinephrine cartridge [19], 49 of 88 patients [55.7%]
could be considered aspirin resistant.Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/1
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Patients undergoing coronary artery bypass grafting
(CABG) have a high incidence of aspirin resistance. Before
CABG, 10 µmol/L aspirin inhibited more than 90% of
thromboxane formation within 15 min. In aspirin-resist-
ant PRP, the inhibition of thromboxane formation was
significantly delayed [18].
Aspirin may not be cardioprotective in patients with
hyperlipidaemia. Platelet aggregation was measured using
a final collagen concentration of 1.0 µg/ml in 56 patients
receiving aspirin 325 mg/day who had a history of coro-
nary heart disease. The 14 patients with poor responsive-
ness to aspirin had significantly higher mean
concentrations of total cholesterol and LDL cholesterol
than the 42 patients with good responsiveness. In total, 9/
13 [69%] patients with hyperlipidemia had poor respon-
siveness to aspirin [26].
Recent data also indicate that other nonsteroidal anti-
inflammatory drugs [NSAIDs] might interfere with aspi-
rin's effects [27,28]. Kurth et al [27] suggested that regular
but not intermittent use of NSAIDs inhibits the clinical
benefits of aspirin.
Experimental models have also shown that aspirin fails to
prevent thrombosis-related activities. Thrombin gener-
ated at an endothelial lesion induces platelet activation,
an activity not affected by aspirin [29]. Maalej and Folts
[30] showed, in a canine model with coronary artery ste-
nosis, that aspirin did not prevent the reduction in cyclic
flow. As several potential agonists are released when the
vascular endothelium is damaged, not only from platelets
but also from the endothelial cells, erythrocytes and leu-
kocytes, it may be supposed that the inhibitory effect of
aspirin may also be overwhelmed in vivo. This study
might explain why both platelet aggregation and platelet
count are significantly lower in the coronary venous
blood than in the aortic blood of patients with coronary
artery disease, though not in normals; this was found
many years ago by Metha et al. [31].
Santos and colleagues [32] found that the synergism
between red cells and platelets in promoting thrombosis
was not prevented by low-dose aspirin but only by 500
mg/day. The implication of these studies is that patients
taking aspirin may not be fully protected against arterial
thrombosis [33]. In 1986 and 1988 [34,35], through ex
vivo aggregation experiments with platelet-rich plasma
from volunteers taking aspirin, we showed that the inhib-
itory effect of aspirin on platelet aggregation induced by
sodium arachidonate was overcome by the synergism
between sodium arachidonate and platelet activating fac-
tor, or ADP or collagen. We employed a mixed agonist sys-
tem in an attempt to better reflect the multiple stimuli
that platelets encounter during in vivo activation. Under
these conditions a normal platelet aggregation pattern
was obtained, although the thromboxane level measured
in the stimulated platelet-rich plasma was less than 5% in
all aspirinated samples. Since this constitutes a "physio-
logical effect at the site of eventual endothelial damage" it
can not be called aspirin resistance.
As was also suggested by Bertele et al. [36], our study indi-
cated no correlation between platelet function and throm-
boxane level, implying that aspirin does not prevent an
agonist potentiation effect when low doses or a daily high
dose are administered. These results are in line with those
obtained by Cerletti et al. [37]
On the other hand, it is possible that in the PFA-100
device where a collagen/epinephrine or ADP/epinephrine
coated cartridge is used, the synergistic effect of these two
agonists has a similar outcome to that observed in our
PRP aggregation studies. We suggest that this can not be
called aspirin resistance and that the PFA-100 system used
to define this concept, was overestimated
About the Definition of Aspirin Resistance
As pointed out by Patrono [38], recurrent vascular events
despite the chronic use of aspirin should be defined as
treatment failure instead aspirin resistance [unless we
attribute treatment failure to aspirin resistance]. Aspirin
resistance is a poorly defined term. It can imply a clinical
inability of aspirin to protect individuals from arterial
thrombotic events; or laboratory indications of the failure
of aspirin to inhibit platelet activity, mainly platelet aggre-
gation; or a close-to-normal urinary concentration of
thromboxane metabolites. Possible mechanisms of aspi-
rin resistance were detailed by Gaetano and Cerletti [39]
and were summarized by Cambria-Kiely and Gandhi [40].
They include: 1. Bioavailability of aspirin; 2. Platelet func-
tion;  3.  Polymorphisms;  4.  Platelet interactions with
other blood cells and cell-derived products; 5.  Several
other factors i.e. stimulation of platelet aggregation by cig-
arette smoking; ASA resistant platelet aggregability by
increased levels of norepinephrine, as seen during exces-
sive exercise or periods of mental stress; biosynthesis of
F[2]-isoprostane 8-iso-prostaglandin [PGF2 alpha], a bio-
active product of arachidonic acid peroxidation; and
increased platelet sensitivity to collagen.
The urinary concentrations of the metabolite 11-dehydro-
thromboxane B2 indicate the level of TXA2 generation.
Eikelboom et al [24] indicated that in aspirin-treated
patients, urinary concentrations of 11-dehydrothrombox-
ane B2 predict the future risk of myocardial infarction or
cardiovascular death. These authors also support the view
that failure to suppress thromboxane generation defines
aspirin resistance [24]. This hypothesis assumes a direct
association between the rise of urinary 11-dehydrothrom-Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/1
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boxane B2 levels and increment of vascular events [myo-
cardial infarction, stroke and cardiovascular death].
Poor platelet responsiveness to aspirin was defined by
Friend et al. [26] as aggregation of ≥ 50% of platelets using
the PFA-100 device. Gum et al [19] defined aspirin resist-
ance on the basis of the platelet aggregation assay: aggre-
gation of ≥ 70% with 10 µM ADP, and of ≥ 20% with 0.5
mg/ml arachidonic acid, constituted aspirin resistance.
They also defined aspirin semiresponders as meeting one
but not both of these criteria. There seems to be no corre-
lation between the results obtained by aggregometry and
by the PFA-100 device, as showed by Gum et al [19]: of
the 18 patients who were aspirin resistant by aggregation,
only 4 were aspirin resistant by PFA-100.
Anti-aggregatory treatment with ASA was considered by
Tarjan et al. [17] to be ineffective if typical aggregation
curves were obtained above the following final inducer
concentrations: ADP: > 5 µM, epinephrine: > 5 µM, ara-
chidonic acid: > 250 µM, collagen: > 2 µg/ml. Compliance
by subjects was proven by HPLC determination of urinary
metabolites of ASA, performed immediately after admis-
sion [17].
Sane et al. [25] considered patients to be aspirin non-
responsive when 4 of the following 5 parameters were
observed: collagen-induced aggregation >70%; adenosine
diphosphate-induced aggregation >60%, whole blood
aggregation >18 ohms; expression of active GP IIb/IIIa
>220 log mean fluorescence intensity units; and P-selectin
positivity >8%. When the PFA-100 device was used, aspi-
rin resistance was defined in terms of a normal collagen
and/or epinephrine closure time [< or = 193 seconds]
[19].
Weber et al. [41] proposed to classify aspirin resistance
into three categories. Type 1 [pharmacokinetic type]
entails the inhibition of platelet thromboxane formation
in vitro but not in vivo. Type 2 [pharmacodynamic type]
is characterized by the inability of aspirin to inhibit plate-
let thromboxane formation both in vivo and in vitro. Type
3 [pseudoresistance] involves thromboxane-independent
platelet activation.
According to Koksch et al. [42] aspirin resistance involves,
besides thromboxane formation, an impaired inhibition
of platelet aggregation and an increased expression of P-
selectin, a marker of α-granule secretion associated with
the progression of atherosclerosis.
Also Weber et al [43] suggested that the inducible isoform
of cyclooxygenase in platelets, COX-2, confers aspirin
resistance, although this opinion was challenged by
Patrignani et al. [44].
Aspirin resistance may be caused by an increased sensitiv-
ity of platelets to collagen. A platelet aggregation study
specific for collagen dose response may be useful for strict
selection of ASA responders for low-dose ASA therapy,
and for identifying ASA non-responders for high-dose
ASA therapy [45].
Using a collagen/epinephrine coated cartridge in the PFA-
100 [R], a prevalence of aspirin resistance of 29.2% was
determined by Macchi et al. [46]. These authors support
the view that hypersensitivity to adenosine diphosphate
could provide a possible explanation for aspirin resist-
ance.
Buchanan and Brister [47] used bleeding time to define
responders and non-responders. Aspirin effected a dose-
dependent prolongation of bleeding time in 60% of vol-
unteers [ASA responders], which was associated with
decreases in platelet TXA2 and 12-hydroxyeicosatetraenoic
acid [12-HETE] synthesis and in platelet aggregation and
adhesion. However, in volunteers whose bleeding time
was not prolonged [ASA non-responders], platelet 12-
HETE synthesis and platelet adhesion were unchanged or
increased [P < 0.001] despite platelet TXA2 and aggrega-
tion being inhibited. Beside the problems of methodol-
ogy, the dissociation between TXA2 and bleeding time
makes this test inadequate for defining non-responsive
patients.
Andersen et al. [48] showed that the levels of TXA2 were
extremely low in both aspirin responders and non-
responders. However, the levels of soluble P-selectin were
significantly higher in non-responders than responders.
Resistance to other antiplatelet drugs has also been
described. "Clopidogrel resistance" has been documented
[49]. Clopidogrel non-responders were defined by an
inhibition of ADP [5 and 20 mol/L] induced platelet
aggregation that was less than 10% of the baseline value 4
h after clopidogrel 600 mg intake. Semi-responders corre-
sponded to patients with an inhibition of 10 to 29%;
responders are patients with an inhibition over 30%. Up
to 4.7% of the patients undergoing coronary stenting
developed thrombotic stent occlusion, despite intensive
clopidogrel treatment; the parallel with aspirin resistance
seems striking. However, as there is no standard defini-
tion of aspirin resistance, comparison between the results
of different studies is difficult.
We support the view that aspirin resistance cannot be
defined by the level of serum thromboxane or its urinary
metabolites, because these measurements do not correlate
with the reduction of inhibition of platelet aggregation in
response to multiple stimuli, and also because:Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/1
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1. Although most of the thromboxane is believed to come
from the platelets, there are additional cellular origins:
monocytes/macrophages are also a rich source of throm-
boxane A2 [50].
2. Unlike the platelet, the macrophage is capable of syn-
thesizing new COX-2 after aspirin has inhibited it. COX-2
is the enzyme responsible for most of the metabolism of
arachidonic acid in the macrophage, and low dose aspirin
is not sufficient to inhibit COX-2 [50] maximally.
3. Macrophages in atheromata may contribute signifi-
cantly to the pool of thromboxane A2 [51].
4. Aspirin only inhibits monocyte PGHS-2, which is
inducible by inflammatory stimuli, transiently at very
high concentrations [52].
Pleiotropic Effects of Aspirin
In patients undergoing aspirin therapy, despite synergistic
platelet aggregation at endothelial lesions in vivo and
close-to-normal concentrations of thromboxane in
plasma and thromboxane metabolites in the urine, aspi-
rin still prevents arterial thrombosis to some extent. It
therefore appears that aspirin exerts antithrombotic
effects through mechanisms other than its weak inhibi-
tion of platelet aggregation. These other mechanisms
could be at least as important [53].
Aspirin significantly decreases the levels of inflammatory
factors in animal models [54]. It markedly inhibits plaque
growth. It inhibits vascular smooth muscle cell prolifera-
tion, and transforming growth factor β plays a significant
intermediary role in this [55,56]. It diminishes in vitro
thrombin generation in platelet rich plasma activated by
sodium arachidonate [57]. Pretreatment with 1.2 g of
aspirin preserves endothelial function and diminishes the
increase of inflammatory markers after administration of
salmonella vaccine [58]. In a subset of healthy men in the
Physicians Health Study, patients within the highest quar-
tile of C-reactive protein elevation showed a significant
benefit from aspirin treatment [325 mg/day every other
day] compared with those in the lowest quartile [59]. In
patients with coronary artery disease, aspirin also seems to
reduce C-reactive protein levels [60]. Low-dose aspirin [as
well as sinvastatin] decreased IL-1β levels and platelet acti-
vation after a 2-month treatment [61]. Other effects of
aspirin are: modulation of thrombolysis [62,63]; increase
in fibrin gel porosity [64]; effects on membrane fluidity
[65]; modulation of the formation of lipid bodies in leu-
kocytes from which eicosanoids may be released [66];
facilitation of the inhibition of platelet activation by neu-
trophils, an effect that appears to be mediated by a nitric
oxide [NO]/cGMP-dependent process [67]; protection of
low density lipoprotein from oxidative modification [68];
improvement of endothelial dysfunction in atherosclero-
sis [69]; and acetylation of platelet membrane glycopro-
teins IIb-IIIa, which augments the inhibitory effects of
abciximab by increasing its binding to platelets [70]. This
range of effects of aspirin could be relevant to its pleiot-
ropy; some of the effects could be more important than its
anti-platelet activity. It is simplistic to suppose that sup-
pression of aspirin's weak anti-aggregating action is the
only cause for its failure to prevent arterial thrombosis.
Failure of Plaque "Passivation". Role of 
Inflammation
It is not surprising that a hypercoagulable state occurs in
the plasma in acute coronary syndromes, as indicated by
blood prothrombotic markers or by the presence of new
cardiovascular events in the face of powerful antithrom-
botic therapy [71-78]. Inflammation can have a pro-
thrombotic effect through the increase of tissue factor,
platelet reactivity or acute phase reactant proteins such as
fibrinogen, or through a decrease in fibrinolysis by
increasing the level of plasminogen activator inhibitor-1
[PAI-1] [79].
Locally, thrombin is not only involved in coagulation; it
has pro-inflammatory activity [80]. Thrombin can activate
receptors on platelets and the vascular endothelium, lead-
ing to inflammation and tissue injury [81]. Activated
platelets express CD40L and induce endothelial cells to
secrete chemokines and to express adhesion molecules,
indicating that platelets could initiate an inflammatory
response of the vessel wall [82]. Interesting, it has recently
been shown that besides their specific activity, lipid-low-
ering drugs [83,84], the novel group of antidiabetic drugs
thiazolidinediones [85,86], and angiotensin-converting
enzyme inhibitor, all exhibit anti-inflammatory proper-
ties. Their clinical benefits may to some extent derive from
lowering inflammation [87].
The underlying inflammation of atheromata in acute cor-
onary syndromes could be the basis of failure of intensive
antithrombotic therapy [88]. COX-2 inhibition may
decrease athero-inflammation, reducing monocyte infil-
tration and improving vascular cell function and plaque
stability, resulting in a decrease of coronary athero-throm-
botic events [53]. In our hands, the combination of a pref-
erential COX-2 inhibitor, meloxicam, plus heparin and
aspirin, proved superior to heparin and aspirin alone for
reducing coronary thrombotic events in patients with
acute coronary syndromes without ST-segment elevation
[89].
In conclusion, aspirin resistance depends on circum-
stances independent of aspirin and could more aptly be
termed aspirin failure. This is supported by the fact that
increasing doses of aspirin can completely inhibit plateletThrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/1
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aggregation in patients who are unresponsive or only par-
tially responsive to aspirin [cited by [90]]. Otherwise,
thrombin generated at the endothelial lesion can induce
platelet activation, which is not affected by aspirin.
All these findings indicate that, in acute coronary syn-
dromes, there is a strong pro-clotting activity in the com-
plicated atheroma. This activity is augmented by the
underlying inflammation, which in several circumstances
can overwhelm the inhibitory effects of single or com-
bined anti-thrombotic drugs, including aspirin. Thus, the
underlying endothelial and/or atheroma inflammation in
coronary syndromes could explain why the antiplatelet
effect of aspirin fails, irrespective of its anti-aggregating
capacity or the urinary levels of thromboxane metabolites.
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